The European Commission has awarded funding to 17 research projects in a special call announced to tackle the coronavirus. IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy, is participating in one of these projects, together with other research centres. The project, called RiPCoN, will perform a computational study of the interactions between coronavirus and human cells, with the aim to identify drugs (already on the market or in trials) that can halt the spread of the virus.
Various media have reported on Spain’s participation in 6 of the 17 projects chosen by the European Commission to advance and speed up research into the coronavirus.
Link to: La Vanguardia
Link to: El Confidencial
Link to: Redacción Médica
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).